Annexon, Inc. (Nasdaq: ANNX) has announced its strategic priorities for 2025, highlighting advancements in its pipeline of therapies targeting complement-mediated neuroinflammatory diseases. The company's focus remains on ANX005 for Guillain-Barré syndrome (GBS), ANX007 for geographic atrophy (GA), and ANX1502 for various autoimmune conditions.
ANX005: Aiming to Redefine GBS Treatment
ANX005, a targeted therapy for GBS, has demonstrated promising results in a pivotal Phase 3 trial. The study revealed that patients treated with ANX005 experienced quicker and more complete functional recovery compared to those receiving a placebo. Furthermore, a real-world evidence (RWE) study corroborated these findings, showing that ANX005 led to a rapid increase in muscle strength and enhanced recovery compared to standard treatments like intravenous immunoglobulin (IVIg) or plasma exchange (PE). Annexon is preparing for a BLA submission in the first half of 2025, potentially offering a new treatment option for this debilitating neurological condition.
ANX007: Preserving Vision in Geographic Atrophy
ANX007 is under investigation as a neuroprotective therapy for geographic atrophy (GA). Phase 2 ARCHER data indicated significant vision protection under both standard and low-light conditions, along with structural protection of photoreceptors in the central fovea. The ongoing Phase 3 ARCHER II trial, a sham-controlled study involving approximately 630 patients, is assessing ANX007's ability to protect against ≥15-letter loss in best corrected visual acuity (BCVA). Enrollment is expected to conclude in the second half of 2025, with data anticipated in the second half of 2026.
ANX1502: Oral C1s Inhibitor for Autoimmune Diseases
ANX1502, a first-in-kind oral C1s inhibitor, is being developed for autoimmune conditions. A bridging study in healthy volunteers showed that a twice-daily tablet formulation had a similar or better safety and pharmacokinetic profile compared to a liquid suspension. An open-label, single-arm study in cold agglutinin disease (CAD) is currently underway to evaluate an enteric-coated tablet formulation with improved tolerability. Clinical proof-of-concept data in CAD, along with updates on future target indications, are expected in the first quarter of 2025.
Douglas Love, president and chief executive officer of Annexon, stated, "With significant catalysts approaching, we’re excited to take advantage of our strong momentum and are well-positioned for a breakthrough year ahead."
